Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 11/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30174197 | 1.00 | P2RX3 (0.40) | P2RX3ALDH1A1MAPK1HCAR2TSHR | |
| SCHEMBL9427465 | 0.77 | P2RX3 (0.38) | P2RX3HCAR2MEN1KMT2A | |
| SCHEMBL30174318 | 0.76 | ALDH1A1 (0.39) | P2RX3ALDH1A1MAPK1MEN1KMT2A | |
| SCHEMBL25529029 | 0.76 | ALDH1A1 (0.39) | P2RX3ALDH1A1MAPK1MEN1KMT2A | |
| SCHEMBL25210352 | 0.70 | MAPK1 (0.45) | P2RX3ALDH1A1MAPK1HCAR2MEN1 | |
| SCHEMBL30063260 | 0.70 | MAPK1 (0.45) | P2RX3ALDH1A1MAPK1HCAR2MEN1 | |
| SCHEMBL30843854 | 0.68 | KDM4E (0.44) | ALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL26967897 | 0.68 | KDM4E (0.44) | ALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL6730304 | 0.66 | PTPN1 (0.37) | P2RX3MAPK1HCAR2TSHR | |
| SCHEMBL30843852 | 0.66 | HTT (0.55) | ALDH1A1TSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151003-A1 | COMPOUNDS AND METHODS OF USE | EXELIXIS INC (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230151003-A1 | COMPOUNDS AND METHODS OF USE | EXELIXIS INC (US) | 2023-05-18 | — | — | US | disclosed |
| CN-115605478-A | Compounds and methods of use | 埃克塞里艾克西斯公司（US） | 2023-01-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151003-A1 | COMPOUNDS AND METHODS OF USE | PRKACB, PRKACA, PRKX | P2RX3 1322/4885ALDH1A1 3998/4885MAPK1 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.